SOPHiA GENETICS SA (SOPH) Stock Price & Analysis
SOPHiA GENETICS SA (SOPH) closed at USD 7.29 on Thursday, October 15, 2026, up 3.26% on the day. The US market is currently closed; this is not a live price.
The prior close was USD 7.06; the Oct 15, 2026 session ranged USD 6.83–7.44 on volume of 1,754,578 shares. Market capitalization is $620.58M, with a 52-week range of USD 3.75–8.98 (NMS). Source: Nexqual, retrieved October 16, 2026 at 05:21 UTC.
Also available as compact Markdown for AI agents: nexqual.com/SOPH.md
Key facts (SOPH)
- 1 of 80 tracked superinvestors hold SOPH (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
- Insider open-market sales, last ~7 months: 55 Form 4 filings, $4.0M; 2 not under a Rule 10b5-1 plan ($3K).
- Analysts: Buy (mean 2.00 on a 1–5 scale) (5 analysts), mean target USD 9.75 (range 7–14).
- Total return with dividends: 1Y +64.2% vs S&P 500 +18.1%; 5Y -54.7% vs S&P 500 +85.1%.
- Next earnings: 2026-11-03, EPS estimate USD -0.2, revenue estimate $24.0M.
Superinvestors (SEC 13F-HR, Q2 2026) (SOPH)
1 of 80 tracked investors hold SOPH. Change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Chuck Akre | Akre Capital Management | 0.42% | $21.5M | Unchanged |
Insider sales (SEC Form 4, open-market, last ~7 months) (SOPH)
53 of 55 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.
| Trade date | Insider | Role | Shares | Value | % of holdings sold | 10b5-1 plan |
|---|---|---|---|---|---|---|
| 2026-10-13 | Xu Zhenyu | Chief Scientific Officer | 4,000 | $29K | 0.7% | Yes |
| 2026-10-12 | Menu Philippe | Chief Medical Officer | 5,000 | $36K | 2.5% | Yes |
| 2026-10-12 | Camblong Jurgi | Executive Chairman | 8,500 | $62K | 0.3% | Yes |
| 2026-10-05 | Van Well Daan | Chief Legal Officer | 6,168 | $50K | 1.8% | Yes |
| 2026-10-05 | Valente Manuela | Chief People Officer | 4,240 | $34K | 2% | Yes |
| 2026-10-05 | Verma Abhimanyu | Chief Technology Officer | 5,284 | $43K | 3.1% | Yes |
| 2026-10-05 | Puylaert Kevin | Chief Sales Officer | 216 | $2K | 0.1% | No |
| 2026-10-05 | Cardoza George | Chief Financial Officer | 1,592 | $13K | 0.5% | Yes |
| 2026-10-05 | Menu Philippe | Chief Medical Officer | 7,394 | $60K | 3.5% | Yes |
| 2026-10-05 | Camblong Jurgi | Executive Chairman | 40,172 | $327K | 1.2% | Yes |
| 2026-10-05 | Xu Zhenyu | Chief Scientific Officer | 7,394 | $60K | 1.3% | Yes |
| 2026-10-05 | Muken Ross | Chief Executive Officer | 9,838 | $80K | 1.5% | Yes |
| 2026-09-21 | Cardoza George | Chief Financial Officer | 774 | $6K | 0.3% | Yes |
| 2026-09-21 | Muken Ross | Chief Executive Officer | 422 | $4K | 0.1% | Yes |
| 2026-09-14 | Menu Philippe | Chief Medical Officer | 5,000 | $39K | 2.3% | Yes |
| 2026-09-14 | Xu Zhenyu | Chief Scientific Officer | 4,000 | $32K | 0.7% | Yes |
| 2026-09-11 | Van Well Daan | Chief Legal Officer | 6,168 | $47K | 1.8% | Yes |
| 2026-09-10 | Camblong Jurgi | Executive Chairman | 8,500 | $65K | 0.2% | Yes |
| 2026-09-08 | Hibbs Kathy L | Director | 6,250 | $51K | 6.1% | Yes |
| 2026-08-27 | Xu Zhenyu | Chief Scientific Officer | 10,000 | $89K | 1.8% | Yes |
% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).
Analysts (SOPH)
Consensus Buy (mean 2.00 on a 1–5 scale), 5 analysts; mean target USD 9.75 (low 7, high 14).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-12 | HC Wainwright & Co. | Reiterated | Buy | $14 |
| 2026-08-05 | HC Wainwright & Co. | Target raised | Buy | $12 → $14 |
| 2026-08-05 | BTIG | Target raised | Buy | $8 → $9 |
| 2026-07-20 | HC Wainwright & Co. | Initiated | Buy | $12 |
Total return (dividends reinvested) (SOPH)
| 1Y (from 2025-10-16) | 5Y (from 2021-10-11) | |
|---|---|---|
| Total return | +64.2% | -54.7% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | +64.5% | -14.6% |
| Volatility (annualized) | 62.2% | 75.9% |
| Max drawdown | -25.7% (Jan 2026→Mar 2026) | -88.0% (Oct 2021→Nov 2022) |
Key Statistics (as of October 16, 2026 at 05:21 UTC)
| Price | USD 7.29 |
|---|---|
| Change | ▲ 3.26% (up) |
| Previous Close | USD 7.06 |
| Open | USD 6.99 |
| Day Range | USD 6.83 – 7.44 |
| 52-Week Range | USD 3.75 – 8.98 |
| Volume | 1,754,578 shares |
| Market Cap | $620.58M |
| Exchange | NMS |
Technical Analysis (SOPH)
Nexqual's technical model rates SOPH "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 16, 2026 at 05:21 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 40.48 (neutral) |
| vs SMA50 | Below (USD 7.95) |
| MACD | -0.21 (negative) |
Analyst Ratings (SOPH)
Wall Street analysts rate SOPH "Buy" based on 5 analysts, with a mean price target of USD 9.75 (range USD 7–14), per Nexqual as of October 16, 2026 at 05:21 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 5 |
| Mean Target | USD 9.75 |
| High Target | USD 14 |
| Low Target | USD 7 |
| Buy / Hold / Sell | 5 / 0 / 0 |
Earnings (SOPH)
| Next Earnings Date | 2026-11-03 |
|---|---|
| EPS Estimate | USD -0.2 |
| Revenue Estimate | $24.03M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD -0.2 vs est -0.22 ▲ beat |
| 2026-03-31 | USD -0.19 vs est -0.24 ▲ beat |
| 2025-12-31 | USD -0.17 vs est -0.2 ▲ beat |
| 2025-09-30 | USD -0.2 vs est -0.2 ▲ beat |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financials & Fundamentals (SOPH)
| Total Revenue | $86.17M |
|---|---|
| Revenue Growth (latest quarter, YoY) | +27.20% |
| Gross Margin | +66.63% |
| Operating Margin | -86.03% |
| Profit Margin | -93.86% |
| ROE | -101.22% |
| Debt / Equity | 0.74 |
| Current Ratio | 2.69 |
| Total Cash | $107.67M |
| Total Debt | $61.83M |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Financial Health Score (SOPH)
Nexqual rates SOPHiA GENETICS SA's overall financial health "Mixed" across five dimensions, as of October 16, 2026 at 05:21 UTC.
| Growth | Strong — Revenue +19% YoY (annual) |
|---|---|
| Profitability | Solid — Gross margin 67%, operating -86% |
| Balance Sheet | Strong — $108M cash vs $62M debt, net cash position |
| Cash Flow | Weak — Operating cash flow -$40M (TTM) |
| Efficiency | Critical — ROE -101%, ROA -24.5% |
Ownership (SOPH)
| Insider Ownership | +6.65% |
|---|---|
| Institutional Ownership | +62.36% |
| Shares Outstanding | 85.13M |
| Float | 65.45M |
| Short % of Float | +1.40% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Leadership (SOPH)
SOPHiA GENETICS SA is led by Ross Jordan Muken B.Sc. (age 45), CEO & Director, per Nexqual as of October 16, 2026 at 05:21 UTC.
| CEO & Director | Ross Jordan Muken B.Sc. (age 45) |
|---|---|
| Co-Founder & Executive Chairman | Jurgi Camblong (age 47) |
| Executive VP & CFO | George A. Cardoza (age 63) |
| EVP & Chief Technology Officer | Abhimanyu Verma |
| Executive VP & Chief Scientific Officer | Zhenyu Xu (age 42) |
Major Backers & Investors (SOPH)
Notable institutional backers of SOPHiA GENETICS SA include Generation Investment Management LLP, AIGH Capital Management LLC, Akre Capital Management, LLC, according to Nexqual as of October 16, 2026 at 05:21 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Generation Investment Management LLP | 8.09% |
| AIGH Capital Management LLC | 4.71% |
| Akre Capital Management, LLC | 4.43% |
| Royce & Associates LP | 4.03% |
| Principal Financial Group, Inc. | 2.82% |
| Ameriprise Financial, Inc. | 2.64% |
| Banque Pictet & Cie SA | 2.63% |
| AWM Investment Company, Inc. | 2.03% |
Source: Nexqual, October 16, 2026 at 05:21 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| WEAV | Weave Communications, Inc. | USD 7.39 | ▲ 0.27% |
| PHR | Phreesia, Inc. | USD 11.04 | ▲ 2.7% |
| EVH | Evolent Health, Inc | USD 4.87 | ▲ 5.87% |
| NRC | NRC Health | USD 21.11 | ▲ 4.66% |
| CTEV | Claritev Corporation | USD 23.86 | ▲ 0.59% |
| CARL | Carlsmed, Inc. | USD 13.95 | ▼ 3.59% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 16, 2026 at 05:21 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt